3D Systems introduced its Regenerative Tissue Program intended to provide an unparalleled solution for surgical procedures requiring reconstruction. 3D Systems has established this program as a result of the significant progress achieved in developing next-generation bioprinting solutions for 3D-printed solid organs. Through the combination of bioprinting technology, biocompatible 3D printing materials, and patient-derived cells, the company is constructing vascularized, patient-specific living human tissues. Through the power of advanced 3D modeling, novel bioinks, and high-speed high-resolution 3D bioprinters, 3D Systems is developing an acellular biointegrative scaffold to regenerate adipose tissue. This scaffold can be combined with intraoperative cellularization with adipose cells harvested from the patient during surgery. This results in a regenerative scaffold that mimics the patient’s anatomy and physiology to help deliver improved surgical outcomes- addressing the clinical need for a long-term reconstructive solution for soft tissue applications. The company will leverage its VSP surgical planning solutions to plan and design these patient-specific scaffolds to help improve surgical outcomes and elevate the patient experienceLeveraging VSP for its tissue program, 3D Systems’ biomedical engineers will be able to collaborate with surgeons – beginning with the patient’s digital data – to design and manufacture biointegrative scaffolds to match the patient’s anatomy.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on DDD:
- 3D Systems Introduces ProJet® MJP 2500W Plus — New 3D Printing Solution for Jewelry Manufacturing Dramatically Improves Productivity
- 3D Systems announces availability of ProJet-MJP 2500W Plus
- Sell these stocks now, proven algorithm says
- 3D Systems appoints Gee as member of medical advisory board
- 3D Systems Announces Appointment of Dr. Rebekah Gee as Member of its Medical Advisory Board